Review of the clinical case of a patient with microcarcinoma of the thyroid gland
https://doi.org/10.14341/ket12255
Abstract
Before us is the story of young woman who actively monitored the condition of the thyroid gland, due to the accidental detection of antibodies to the thyroid tissue. After the detection of a tumor (7 mm), hemi thyroidectomy was conducted. For two years after the operation she has been under the care of oncologist and endocrinologist. However, despite explanations about a good prognosis of the disease, she is extremely alarmed and unjustifiably often conducts laboratory tests, ignoring the fact that both the reference range and the evaluation methods are different. It should be said that similar problems exist in all countries (Nedman C. et al., 2017) – fear of relapse of the disease worries the vast majority of patients even years after it’s been diagnosed. People are concerned not only about the risks of thyroid cancer recurrence, but also about the risks of development of other cancers, the risks of being not able to get access to skilled care. The obvious task of a doctor is to correct a pattern of patient behavior that increases anxiety.
About the Authors
Galina A. MelnichenkoRussian Federation
MD, PhD, Professor
Natalia G. Mokrysheva
Russian Federation
MD, PhD
Nino N. Katamadze
Russian Federation
clinical resident
References
1. Spencer C, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90(10):5566-5575. doi: https://doi.org/10.1210/jc.2005-0671.
2. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122. doi: https://doi.org/10.1111/cen.12515.
3. Netzel BC, Grebe SK, Carranza Leon BG, et al. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J Clin Endocrinol Metab. 2015;100(8):E1074-1083. doi: https://doi.org/10.1210/jc.2015-1967.
4. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114(3):393-402. doi: https://doi.org/10.1097/00005537-200403000-00001.
5. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-142. doi: https://doi.org/10.1089/thy.2006.16.109.
6. Бельцевич Д.Г., Ванушко В.Э., Румянцев П.О., и др. Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых, 2017 год // Эндокринная хирургия. – 2017. – Т. 1. – №11. – С. 6-27. [Beltsevich DG, Vanushko VE, Rumiantsev PO, et al. 2017 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment. Endocrine surgery. 2017;1(11):6-27. (In Russ.)]. doi: https://doi.org/10.14341/serg201716-27.
Review
For citations:
Melnichenko G.A., Mokrysheva N.G., Katamadze N.N. Review of the clinical case of a patient with microcarcinoma of the thyroid gland. Clinical and experimental thyroidology. 2019;15(3):124-128. (In Russ.) https://doi.org/10.14341/ket12255

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).